185 related articles for article (PubMed ID: 12641451)
41. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
[TBL] [Abstract][Full Text] [Related]
42. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
43. Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.
Ameriks MK; Axe FU; Bembenek SD; Edwards JP; Gu Y; Karlsson L; Randal M; Sun S; Thurmond RL; Zhu J
Bioorg Med Chem Lett; 2009 Nov; 19(21):6131-4. PubMed ID: 19773165
[TBL] [Abstract][Full Text] [Related]
44. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
Guncar G; Pungercic G; Klemencic I; Turk V; Turk D
EMBO J; 1999 Feb; 18(4):793-803. PubMed ID: 10022822
[TBL] [Abstract][Full Text] [Related]
45. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
[TBL] [Abstract][Full Text] [Related]
46. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
47. The major cathepsin L secreted by the invasive juvenile Fasciola hepatica prefers proline in the S2 subsite and can cleave collagen.
Corvo I; Cancela M; Cappetta M; Pi-Denis N; Tort JF; Roche L
Mol Biochem Parasitol; 2009 Sep; 167(1):41-7. PubMed ID: 19383516
[TBL] [Abstract][Full Text] [Related]
48. Human cathepsin H: deletion of the mini-chain switches substrate specificity from aminopeptidase to endopeptidase.
Dodt J; Reichwein J
Biol Chem; 2003 Sep; 384(9):1327-32. PubMed ID: 14515996
[TBL] [Abstract][Full Text] [Related]
49. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity.
Ayesa S; Lindquist C; Agback T; Benkestock K; Classon B; Henderson I; Hewitt E; Jansson K; Kallin A; Sheppard D; Samuelsson B
Bioorg Med Chem; 2009 Feb; 17(3):1307-24. PubMed ID: 19124252
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of cathepsin G by 2-amino-3,1-benzoxazin-4-ones: kinetic investigations and docking studies.
Gütschow M; Kuerschner L; Pietsch M; Ambrozak A; Neumann U; Günther R; Hofmann HJ
Arch Biochem Biophys; 2002 Jun; 402(2):180-91. PubMed ID: 12051662
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
Tully DC; Liu H; Alper PB; Chatterjee AK; Epple R; Roberts MJ; Williams JA; Nguyen KT; Woodmansee DH; Tumanut C; Li J; Spraggon G; Chang J; Tuntland T; Harris JL; Karanewsky DS
Bioorg Med Chem Lett; 2006 Apr; 16(7):1975-80. PubMed ID: 16446091
[TBL] [Abstract][Full Text] [Related]
52. Irreversible inhibition of human cathepsins B, L, S and K by hypervalent tellurium compounds.
Cunha RL; Gouvêa IE; Feitosa GP; Alves MF; Brömme D; Comasseto JV; Tersariol IL; Juliano L
Biol Chem; 2009 Nov; 390(11):1205-12. PubMed ID: 19663682
[TBL] [Abstract][Full Text] [Related]
53. 3D-QSAR and docking studies of aldehyde inhibitors of human cathepsin K.
Pan X; Tan N; Zeng G; Han H; Huang H
Bioorg Med Chem; 2006 Apr; 14(8):2771-8. PubMed ID: 16377193
[TBL] [Abstract][Full Text] [Related]
54. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
[TBL] [Abstract][Full Text] [Related]
55. Cathepsin S inhibitors as novel immunomodulators.
Thurmond RL; Sun S; Karlsson L; Edwards JP
Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
[TBL] [Abstract][Full Text] [Related]
56. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
[TBL] [Abstract][Full Text] [Related]
57. Lysosomal cysteine proteases (cathepsins): promising drug targets.
Turk D; Guncar G
Acta Crystallogr D Biol Crystallogr; 2003 Feb; 59(Pt 2):203-13. PubMed ID: 12554931
[TBL] [Abstract][Full Text] [Related]
58. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.
Altmann E; Cowan-Jacob SW; Missbach M
J Med Chem; 2004 Nov; 47(24):5833-6. PubMed ID: 15537340
[TBL] [Abstract][Full Text] [Related]
59. Recombinant human cathepsin H lacking the mini chain is an endopeptidase.
Vasiljeva O; Dolinar M; Turk V; Turk B
Biochemistry; 2003 Nov; 42(46):13522-8. PubMed ID: 14621998
[TBL] [Abstract][Full Text] [Related]
60. Substrate variants versus transition state analogues as noncovalent reversible enzyme inhibitors.
Smyth TP
Bioorg Med Chem; 2004 Aug; 12(15):4081-8. PubMed ID: 15246086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
